Gut microbiome affects the response to immunotherapy in non‐small cell lung cancer
Thoracic Cancer · 2024-05 · 15 (14) · 1149-1163
DOI: 10.1111/1759-7714.15303 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 04.04.2024. Verfasst von Shengnan Ren und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, the Affiliated Hospital of Qingdao University, Qingdao, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Gastrointestinal Microbiome, Lung Neoplasms, Immunotherapy. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Shandong Province, Natural Science Foundation of Qingdao Municipality, Wu Jieping Medical Foundation.
Abstract (Originalsprache)
Background
Immunotherapy has revolutionized cancer treatment. Recent studies have suggested that the efficacy of immunotherapy can be further enhanced by the influence of gut microbiota. In this study, we aimed to investigate the impact of bacteria on the effectiveness of cancer immunotherapy by combining analysis of clinical samples with validation in animal models.
Methods
In order to characterize the diversity and composition of microbiota and its relationship with response to immune checkpoint inhibitors (ICIs), 16S ribosomal RNA (rRNA) and GC–MS sequencing was performed on 71 stool samples from patients with advanced non‐small cell lung cancer (NSCLC) prior to treatment with immune checkpoint blockade (ICB). Furthermore, fecal microbiota transplantation (FMT) was performed from different patients into mice and a subcutaneous tumor model established using the Lewis lung cancer cell line to evaluate the therapeutic effect of PD‐1 on mice with varying gut microbiota.
Results
The results demonstrated a significant association between elevated gut microbiota diversity and response to treatment with ICIs, p < 0.05. Faecalibacterium was markedly increased in the gut microbiota of responders (R), accompanied by increased short‐chain fatty acid (SCFA) levels, especially butanoic acid, acetic acid and hexanoic acid, p < 0.05. Additionally, FMT from R and nonresponders (NR) could promote an anticancer effect and reduce the expression of Ki‐67 cells in tumors in mice, p < 0.05. Moreover, R and NR FMT did not alter PD‐L1 expression in the tumor tissues of mice, p > 0.05. The diversity of gut microbiota consistently correlated with an optimistic prognosis in NSCLC patients with immunotherapy, which could be functionally mediated by SCFAs.
Conclusion
The findings of the present study indicated that the diversity of gut microbiota and SCFAs is related to the efficacy of immunotherapy. FMT can effectively delay tumor progression, and enhance the effect of immunotherapy, thus providing evidence for improving the efficacy of immunotherapy in NSCLC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, the Affiliated Hospital of Qingdao University, Qingdao, China.
ORCID-Profile: Zhuang Yu
Förderung
- Natural Science Foundation of Shandong Province
- Natural Science Foundation of Qingdao Municipality
- Wu Jieping Medical Foundation
- National Natural Science Foundation of China
- Chinese Society of Clinical Oncology
- ShanDong Provincial Medical Association
Zitieren
APA
Ren, S., Feng, L., Liu, H., Mao, Y., & Yu, Z. (2024). Gut microbiome affects the response to immunotherapy in non‐small cell lung cancer. Thoracic Cancer, 15(14), 1149-1163. https://doi.org/10.1111/1759-7714.15303
Vancouver
Ren S, Feng L, Liu H, Mao Y, Yu Z. Gut microbiome affects the response to immunotherapy in non‐small cell lung cancer. Thoracic Cancer. 2024;15(14):1149-1163. doi:10.1111/1759-7714.15303
BibTeX
@article{Ren2024,
author = {Ren, Shengnan and Feng, Lingxin and Liu, Haoran and Mao, Yuke and Yu, Zhuang},
title = {Gut microbiome affects the response to immunotherapy in non‐small cell lung cancer},
journal = {Thoracic Cancer},
year = {2024},
volume = {15},
number = {14},
pages = {1149--1163},
doi = {10.1111/1759-7714.15303}
}
EUVIMED